Rectal signet ring cell adenocarcinoma
disease diseaseOn this page
Also known as rectum signet ring cell carcinomasignet Ring adenocarcinoma of rectumsignet Ring adenocarcinoma of the rectumsignet Ring cell adenocarcinoma of rectumsignet Ring cell adenocarcinoma of the rectum
Summary
Rectal signet ring cell adenocarcinoma (MONDO:0004336) is a disease and 24 clinical trials. Top therapeutic interventions include leucovorin, irinotecan, and oxaliplatin. A subtype of rectum adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 24
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | rectal signet ring cell adenocarcinoma |
| Mondo ID | MONDO:0004336 |
| DOID | DOID:7707 |
| NCIT | C9168 |
| UMLS | C0279654 |
| MedGen | 124641 |
| Anatomy (UBERON) | UBERON:0001052 |
| Is cancer (heuristic) | no |
Also known as: rectal signet Ring cell adenocarcinoma · rectum signet ring cell carcinoma · signet Ring adenocarcinoma of rectum · signet Ring adenocarcinoma of the rectum · signet Ring cell adenocarcinoma of rectum · signet Ring cell adenocarcinoma of the rectum
Disease family
This is a subtype of rectum adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › colorectal adenocarcinoma › rectum adenocarcinoma › rectal signet ring cell adenocarcinoma
Related subtypes (3): anus adenocarcinoma, rectum mucinous adenocarcinoma, rectal medullary carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 24.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 9 |
| PHASE2 | 7 |
| Not specified | 3 |
| PHASE3 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00005036 | PHASE3 | COMPLETED | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
| NCT00068692 | PHASE3 | COMPLETED | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer |
| NCT00002796 | PHASE1/PHASE2 | TERMINATED | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer |
| NCT00052585 | PHASE2 | TERMINATED | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer |
| NCT00745134 | PHASE2 | TERMINATED | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer |
| NCT01652196 | PHASE2 | COMPLETED | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer |
| NCT01802320 | PHASE2 | COMPLETED | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery |
| NCT01814501 | PHASE2 | COMPLETED | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab |
| NCT01871571 | PHASE2 | UNKNOWN | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer |
| NCT02235324 | PHASE2 | WITHDRAWN | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer |
| NCT00003799 | PHASE1 | COMPLETED | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer |
| NCT00060411 | PHASE1 | COMPLETED | A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer |
| NCT01198535 | PHASE1 | TERMINATED | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer |
| NCT01285102 | PHASE1 | TERMINATED | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer |
| NCT01643499 | PHASE1 | COMPLETED | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies |
| NCT01923337 | PHASE1 | COMPLETED | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer |
| NCT02110953 | PHASE1 | TERMINATED | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver |
| NCT02232152 | PHASE1 | COMPLETED | CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery |
| NCT02270606 | PHASE1 | COMPLETED | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer |
| NCT00835679 | EARLY_PHASE1 | TERMINATED | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery |
| NCT01403103 | EARLY_PHASE1 | WITHDRAWN | Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer |
| NCT01726296 | Not specified | COMPLETED | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care |
| NCT01934179 | Not specified | TERMINATED | Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy |
| NCT02132858 | Not specified | COMPLETED | Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LEUCOVORIN | 4 | 14 |
| IRINOTECAN | 4 | 5 |
| OXALIPLATIN | 4 | 2 |
| PHENYLBUTANOIC ACID | 4 | 2 |
| FLUOROURACIL | 4 | 1 |
| GEFITINIB | 4 | 1 |
| INDOMETHACIN | 4 | 1 |
| ALISERTIB | 3 | 1 |
| CPI 613 | 3 | 1 |
| CURCUMIN | 3 | 1 |